NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Present DERMAdoctor Eczema Treatment as QVC® On-Air Guest
February 28 2022 - 6:50AM
Business Wire
Calm Cool + Corrected Eczema + Dermatitis
Clinical Repair Balm to be Featured in Premier Show on March 1 at
10 p.m. Eastern Time
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company
developing and commercializing high-quality, scientifically
formulated eyecare and skincare products, announces that Chief
Product Officer Audrey Kunin, MD will present DERMAdoctor’s
problem-solving eczema treatment as a live on-air guest on the QVC
network. The revolutionary Calm Cool + Corrected 1% Colloidal
Oatmeal Eczema + Dermatitis Clinical Repair Balm will be featured
on “Cheers! to Shopping with Leah and Shawn” on Tuesday, March 1 at
10 p.m. Eastern time.
In addition to serving as NovaBay’s Chief Product Officer, Dr.
Kunin is a board-certified dermatologist, author, clinician,
educator, television personality and recognized trailblazer in the
skincare industry. She founded DERMAdoctor to provide highly
effective, prestige dermatologist problem-solving skincare
solutions for common skincare concerns that have been overlooked by
the beauty industry.
“We deliver on the promise that clinical skin therapy can be
simple and easy, while still delivering significant, measurable
results in the comfort of your own home. Our products improve lives
through science, innovation and creativity and the formulas mix
compassion and expertise. We create real solutions for real people
with real skin-related concerns,” said Dr. Kunin. “It is very
exciting to demonstrate the significant benefits of our effective,
uniquely formulated products directly to QVC’s vast audience,
beginning with our Calm Cool + Corrected 1% Colloidal Oatmeal
Eczema + Dermatitis Clinical Repair Balm. Eczema is a significant
concern, affecting an estimated 31 million Americans.”
Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis
Clinical Repair Balm is formulated with a special form of
eczema-active of 1% colloidal oatmeal with enhanced beta glucan to
help temporarily relieve minor skin irritations and itching,
together with an advanced complex of ceramides and essential lipids
to maximize hydration and dermatologic botanicals that calm and
soothe. The product may be used head to toe. Calm Cool + Corrected
1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm has
received the National Eczema Association (NEA) Seal of Acceptance™,
which is granted in recognition of products that meet the NEA’s
rigorous standards for providing benefits and improving the quality
of life for people with eczema and sensitive skin.
About NovaBay Pharmaceuticals, Inc.:
NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that
develops and sells scientifically created and clinically proven
consumer products for the eyecare and skincare markets. Avenova® is
the most prescribed antimicrobial lid and lash spray in the eyecare
market. In November 2021, NovaBay acquired DERMAdoctor, LLC, a
company offering more than 30 dermatologist-developed skincare
products sold through traditional domestic retailers, digital
beauty channels and international distributors.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies, current product offerings, marketing efforts, and any
future revenue that may result from selling such products, as well
as generally the Company’s expected future financial results. These
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results or achievements to be
materially different and adverse from those expressed in or implied
by the forward-looking statements. Factors that might cause or
contribute to such differences include, but are not limited to,
risks and uncertainties relating to the size of the potential
market for our products, the integration of DERMAdoctor’s business
into the Company’s business, the possibility that the available
market for the Company’s products will not be as large as expected,
the Company’s products will not be able to penetrate one or more
targeted markets, and revenues will not be sufficient to meet the
Company’s cash needs. Other risks relating to NovaBay’s business,
including risks that could cause results to differ materially from
those projected in the forward-looking statements in this press
release, are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay Informed on
NovaBay’s Progress
Like us on Facebook Follow us on Twitter Connect with NovaBay on
LinkedIn Visit NovaBay’s Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com Avenova.com
DERMAdoctor Purchasing
Information For DERMAdoctor purchasing information:
Please call 877-337-6237 or email service@dermadoctor.com
DERMAdoctor.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220228005196/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2023 to Sep 2024